Reported a net loss of $2.02 million for the three months ended March 31, 2026, compared to a $2.23 million loss in the same period of 2025. Operating expenses totaled $2.00 million, down from $2.27 million in Q1 2025, driven by a reduction in research and development costs. Cash and cash equivalents stood at $4.58 million as of March 31, 2026. The company effected a 1-for-25 reverse stock split on February 5, 2026. Entered into a collaboration framework with Molteni Farmaceutici for potential European commercialization of AD04, with an estimated aggregate value of $60 million.